In a report released today, Steven Lichtman from Oppenheimer assigned a Buy rating to MannKind (MNKD), with a price target of $2.50. The company’s shares closed last Tuesday at $1.57.
According to TipRanks.com, Lichtman has 0 stars on 0-5 stars ranking scale with an average return of -3.2% and a 48.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.
MannKind has an analyst consensus of Strong Buy, with a price target consensus of $3.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.48 and a one-year low of $0.80. Currently, MannKind has an average volume of 3.32M.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MNKD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
